MedTrace Logo

Genetic Basis for Variation in the Renal Elimination of Metformin

NCT00187720 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-01-10

Study results available
· View outcomes & findings →

Summary

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation in hOCT2 is associated with variation in the renal clearance of the antidiabetic agent, metformin.

Conditions

  • Other Conditions That May Be A Focus of Clinical Attention

Interventions

DRUG

Metformin

Subjects will be given a single oral dose of 850 mg of metformin

Sponsors & Collaborators

Principal Investigators

  • Kathleen M Giacomini, PhD · University of California, San Francsico

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187720 on ClinicalTrials.gov